|
1
|
Saukkonen K and Hemminki A:
Tissue-specific promoters for cancer gene therapy. Expert Opin Biol
Ther. 4:683–696. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dorer DE and Nettelbeck DM: Targeting
cancer by transcriptional control in cancer gene therapy and viral
oncolysis. Adv Drug Deliv Rev. 61:554–571. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee M: Hypoxia targeting gene expression
for breast cancer gene therapy. Adv Drug Deliv Rev. 61:842–849.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu ZB, Makhija SK, Lu B, Wang M,
Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ,
Leath CA, et al: Transcriptional targeting of tumors with a novel
tumor-specific survivin promoter. Cancer Gene Ther. 11:256–262.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qiao J, Doubrovin M, Sauter BV, Huang Y,
Guo ZS, Balatoni J, Akhurst T, Blasberg RG, Tjuvajev JG, Chen SH
and Woo SL: Tumor-specific transcriptional targeting of suicide
gene therapy. Gene Ther. 9:168–175. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hardcastle J, Kurozumi K, Chiocca EA and
Kaur B: Oncolytic viruses driven by tumor-specific promoters. Curr
Cancer Drug Targets. 7:181–189. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Glinka EM, Edelweiss EF and Deyev SM:
Eukaryotic expression vectors and immunoconjugates for cancer
therapy. Biochemistry (Mosc). 71:597–606. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sadeghi H and Hitt MM: Transcriptionally
targeted adenovirus vectors. Curr Gene Ther. 5:411–427. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andersen MH, Svane IM, Becker JC and
Straten PT: The universal character of the tumor-associated antigen
survivin. Clin Cancer Res. 13:5991–5994. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bao R, Connolly DC, Murphy M, Green J,
Weinstein JK, Pisarcik DA and Hamilton TC: Activation of
cancer-specific gene expression by the survivin promoter. J Natl
Cancer Inst. 94:522–528. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen JS, Liu JC, Shen L, Rau KM, Kuo HP,
Li YM, Shi D, Lee YC, Chang KJ and Hung MC: Cancer-specific
activation of the survivin promoter and its potential use in gene
therapy. Cancer Gene Ther. 11:740–747. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fukuda S and Pelus LM: Survivin, a cancer
target with an emerging role in normal adult tissues. Mol Cancer
Ther. 5:1087–1098. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li F and Altieri DC: Transcriptional
analysis of human survivin gene expression. Biochem J. 344:305–311.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vaĭshlia NA, Zinov'eva MV, Sass AV,
Kopantsev EP, Vinogradova TV and Sverdlov ED: Increase of BIRC5
gene expression in non-small cell lung cancer and esophageal
squamous cell carcinoma does not correlate with expression of genes
SMAC/DIABLO and PML encoding its inhibitors. Mol Biol (Mosk).
42:652–661. 2008.PubMed/NCBI
|
|
17
|
Van Houdt WJ, Haviv YS, Lu B, Wang M,
Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, et
al: The human survivin promoter: A novel transcriptional targeting
strategy for treatment of glioma. J Neurosurg. 104:583–592. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu B, Makhija SK, Nettelbeck DM, Rivera
AA, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma HJ, Alvarez RD,
et al: Evaluation of tumor-specific promoter activities in
melanoma. Gene Ther. 12:330–338. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rein DT, Breidenbach M, Nettelbeck DM,
Kawakami Y, Siegal GP, Huh WK, Wang M, Hemminki A, Bauerschmitz GJ,
Yamamoto M, et al: Evaluation of tissue-specific promoters in
carcinomas of the cervix uteri. J Gene Med. 6:1281–1289. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Konopka K, Spain C, Yen A, Overlid N,
Gebremedhin S and Düzgüneş N: Correlation between the levels of
survivin and survivin promoter-driven gene expression in cancer and
non-cancer cells. Cell Mol Biol Lett. 14:70–89. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mityaev MV, Kopantzev EP, Buzdin AA,
Vinogradova TV and Sverdlov ED: Enhancer element potentially
involved in human survivin gene promoter regulation in lung cancer
cell lines. Biochemistry (Mosc). 75:182–191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bett AJ, Prevec L and Graham FL: Packaging
capacity and stability of human adenovirus type 5 vectors. J Virol.
67:5911–5921. 1993.PubMed/NCBI
|
|
23
|
Li F and Altieri DC: The cancer
antiapoptosis mouse survivin gene: Characterization of locus and
transcriptional requirements of basal and cell cycle-dependent
expression. Cancer Res. 59:3143–3151. 1999.PubMed/NCBI
|
|
24
|
Xia F and Altieri DC: Mitosis-independent
survivin gene expression in vivo and regulation by p53.
Cancer Res. 66:3392–3395. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kyo S, Takakura M, Fujiwara T and Inoue M:
Understanding and exploiting hTERT promoter regulation for
diagnosis and treatment of human cancers. Cancer Sci. 99:1528–1538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gu J and Fang B: Telomerase
promoter-driven cancer gene therapy. Cancer Biol Ther. 2(4 Suppl
1): S64–S70. 2003.PubMed/NCBI
|
|
27
|
Janknecht R: On the road to immortality:
HTERT upregulation in cancer cells. FEBS Lett. 564:9–13. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Horikawa I, Cable PL, Afshari C and
Barrett JC: Cloning and characterization of the promoter region of
human telomerase reverse transcriptase gene. Cancer Res.
59:826–830. 1999.PubMed/NCBI
|
|
29
|
Takakura M, Kyo S, Kanaya T, Hirano H,
Takeda J, Yutsudo M and Inoue M: Cloning of human telomerase
catalytic subunit (hTERT) gene promoter and identification of
proximal core promoter sequences essential for transcriptional
activation in immortalized and cancer cells. Cancer Res.
59:551–557. 1999.PubMed/NCBI
|
|
30
|
Horikawa I and Barrett JC: Transcriptional
regulation of the telomerase hTERT gene as a target for cellular
and viral oncogenic mechanisms. Carcinogenesis. 24:1167–1176. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Poole JC, Andrews LG and Tollefsbol TO:
Activity, function, and gene regulation of the catalytic subunit of
telomerase (hTERT). Gene. 269:1–12. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wick M, Zubov D and Hagen G: Genomic
organization and promoter characterization of the gene encoding the
human telomerase reverse transcriptase (hTERT). Gene. 232:97–106.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cong YS, Wen J and Bacchetti S: The human
telomerase catalytic subunit hTERT: Organization of the gene and
characterization of the promoter. Hum Mol Genet. 8:137–142. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Davis JJ, Wang L, Dong F, Zhang L, Guo W,
Teraishi F, Xu K, Ji L and Fang B: Oncolysis and suppression of
tumor growth by a GFP-expressing oncolytic adenovirus controlled by
an hTERT and CMV hybrid promoter. Cancer Gene Ther. 13:720–723.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wirth T, Zender L, Schulte B, Mundt B,
Plentz R, Rudolph KL, Manns M, Kubicka S and Kühnel F: A
telomerase-dependent conditionally replicating adenovirus for
selective treatment of cancer. Cancer Res. 63:3181–3188.
2003.PubMed/NCBI
|
|
36
|
Mikhaĭlova IN, Lukashina MI, Baryshnikov
AIu, Morozova LF, Burova OS, Palkina TN, Kozlov AM, Golubeva VA,
Cheremushkin EA, Doroshenko MB, et al: Melanoma cell lines as the
basis for antitumor vaccine preparation. Vestn Ross Akad Med Nauk.
37–40. 2005.
|
